[1] Beers M, Berkow R.  The Merck Manual, 17th Ed. 1999.  Herpes Zoster: 1294-1295.
 

[2] Beers M, Berkow R.  The Merck Manual, 17th Ed. 1999.  Herpes Zoster: 1294-1295.
 

[3] www.ninds.nih.gov  The National Institute of Neurological Disorders and Stroke.  December 2004. 
 

[4] Beers M, Berkow R.  The Merck Manual, 17th Ed. 1999.  Herpes Zoster: 1294-1295.
 

[5] Baba M, Shigeta S.  Antiviral activity of glycyrrhizin against varicella zoster virus in vitro.  Antiviral Res.  1987 Feb; 7(2): 99-107.
 

[6] Aikawa Y, Yoshiike T, Ogawa H.  Effect of glycyrrhizin on pain and HLA-DR antigen expression on CD8 positive cells in peripheral blood of herpes zoster patients in comparison with other antiviral agents.  Skin Pharmacol.  1990; 3(4): 268-271.
 

[7] Rains C, Bryson HM.  Topical capsaicin: a review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy, and osteoarthritis.  Drugs Aging.  1995 Oct; 7(4): 317-328.
 

[8] Peikert A, Hentrich M, Ochs G.  Topical 0.025% capsaicin in chronic post-herpetic neuralgia: efficacy predictors of response, and long-term course.  J Neurol.  1991 Dec; 238(8): 452-456.
 

[9] Davies SJ, Harding LM, Baranowski AP.  A novel treatment of post-herpetic neuralgia using peppermint oil.  Clin J Pain. 2002 May-Jun; 18(3): 200-202.